NCT04064476

The Effect of Long-acting Antipsychotics on Schizophrenia Patients With Violence Risk

The Effect of Long-acting Antipsychotic on Schizophrenia Patients With Violence Risk : a Observational Cohort Study

• Status: Unknown
• Phase: —
• Study type: Observational
• Enrollment: 225 (estimated)
• Sponsor: Huazhong University of Science and Technology · Academic / Other
• Sex: All
• Age: 18 Years – 60 Years
• Healthy volunteers: Not accepted

Summary

This is a 49 weeks prospective, non-interventional cohort study. To observe the effect of long-acting injection antipsychotic(LAI), paliperidone palmitate on prevention of recurrence and symptom control in schizophrenia patients with violence risk. This study can be extended according to the implementation of the project and extended follow-up time.

Detailed description

This is a 49 weeks prospective, observational cohort study. Wuhan initiated a project to improve the LAI treatment in schizophrenia patient with violence risk. This observational study will build the cohort of schizophrenia patient with violence risk and treated with LAI paliperidone palmitate. The effect of long-acting antipsychotic, paliperidone palmitate, will be observed on prevention of recurrence and symptom control in these patients. safety information and laboratory tests result will also be collected. This study can be extended according to the implementation of the project and extended follow-up time.

Conditions

• Schizophrenia

Interventions

Type	Name	Description
DRUG	Paliperidone Palmitate	This is a observational study, to see the effect of paliperidone palmitate on schizophrenia patient with violence risk. The intervention is determined by clinical practice in real world setting, only schizophrenia patient with violence risk and treated with Paliperidone Palmitate will be invited to join the observational study.

Timeline

• Start date: 2019-08-18
• Primary completion: 2021-08-15
• Completion: 2021-09-15
• First posted: 2019-08-22
• Last updated: 2020-02-20

Locations

1 site across 1 country: China

Regulatory

• FDA-regulated drug study